Phathom Pharmaceuticals, Inc. (PHAT)
2025-06-30 | 2025-03-31 | 2024-09-30 | ||
|---|---|---|---|---|
| Product revenue, net | 39,503 | 28,519 | 16,352 | |
| Cost of revenue | 5,038 | 3,724 | 2,356 | |
| Gross profit | 34,465 | 24,795 | 13,996 | |
| Selling, general and administrative | 85,313 | 94,474 | 76,099 | |
| Research and development | 9,076 | 9,184 | 8,693 | |
| Total operating expenses | 94,389 | 103,658 | 84,792 | |
| Loss from operations | -59,924 | -78,863 | -70,796 | |
| Other expense, net | -155 | -22 | -8 | |
| Interest income | 1,787 | 2,640 | 3,711 | |
| Interest expense | 17,518 | 18,071 | 18,484 | |
| Total other expense | -15,886 | -15,453 | -14,781 | |
| Net loss and comprehensive loss | -75,810 | -94,316 | -85,577 | |
| Net loss per share, basic | -1.05 | -1.31 | -1.32 | |
| Net loss per share, diluted | -1.05 | -1.31 | -1.32 | |
| Weighted-average shares of common stock outstanding, basic | 72,466,203 | 71,969,411 | 64,627,847 | |
| Weighted-average shares of common stock outstanding, diluted | 72,466,203 | 71,969,411 | 64,627,847 | |